Treatment with DAV for Advanced-Stage Hemangiosarcoma in Dogs

Simple item page
dc.contributor.authorDervisis, Nikolaos G.en
dc.contributor.authorDominguez, Pedro A.en
dc.contributor.authorNewman, R. G.en
dc.contributor.authorCadile, Casey D.en
dc.contributor.authorKitchell, B. E.en
dc.date.accessioned2016-11-15T20:49:49Zen
dc.date.available2016-11-15T20:49:49Zen
dc.date.issued2011-05-01en
dc.description.abstractHemangiosarcoma (HSA) is an aggressive disease that is fairly common in the dog. The authors evaluated a doxorubicin, dacarbazine, and vincristine (DAV) combination protocol in dogs with nonresectable stage II and stage III HSA. Twenty-four dogs were enrolled in this prospective, phase 2 study. Doxorubicin and dacarbazine were administered on day 1 while vincristine was administered on days 8 and 15. The protocol was repeated every 21 days for a maximum of six cycles or until disease progression. Toxicity and efficacy were assessed by clinical and laboratory evaluation and by questionnaires completed by the owners. Of the 24 included dogs, 19 were evaluable for response. The response rate (including five complete responses and four partial responses) was 47.4%. Median time to tumor progression was 101 days and median overall survival was 125 days. Significant toxicities were noted, including 41 high-grade hematologic and 12 high-grade gastrointestinal toxic events. Five dogs discontinued treatment due to chemotherapy-related toxicities, but no treatment-related deaths occurred. Multivariate analysis identified patient age (relative risk [RR], 2.3, P¼0.049) to be negatively associated with time to progression whereas dacarbazine dose reductions (RR, 0.06, P¼0.031) were positively associated with time to progression. Dacarbazine dose reduction was the sole factor positively associated with overall survival (RR, 0.28, P¼0.015). In conclusion, the DAV combination appears to offer clinical responses and may prolong survival in dogs with advanced-stage HSA.en
dc.description.versionPublished versionen
dc.format.extent170 - 178 (9) page(s)en
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.5326/JAAHA-MS-5525en
dc.identifier.issn0587-2871en
dc.identifier.issue3en
dc.identifier.urihttp://hdl.handle.net/10919/73459en
dc.identifier.volume47en
dc.language.isoenen
dc.publisherAmerican Animal Hospital Associationen
dc.relation.urihttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000290014400006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=930d57c9ac61a043676db62af60056c1en
dc.rightsIn Copyrighten
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.subjectVeterinary Sciencesen
dc.subjectSPLENIC HEMANGIOSARCOMAen
dc.subjectCANINE HEMANGIOSARCOMAen
dc.subjectCYP1A2 DEFICIENCYen
dc.subjectDOXORUBICINen
dc.subjectCHEMOTHERAPYen
dc.subjectDACARBAZINEen
dc.subjectANGIOSARCOMAen
dc.subjectCYCLOPHOSPHAMIDEen
dc.subjectVINCRISTINEen
dc.subjectMETABOLISMen
dc.titleTreatment with DAV for Advanced-Stage Hemangiosarcoma in Dogsen
dc.title.serialJournal of The American Animal Hospital Associationen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/Veterinary Medicineen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/CVM T&R Facultyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/Small Animal Clinical Sciencesen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Treatment with DAV.pdf
Size:
574.1 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download
License bundle
Now showing 1 - 1 of 1
Name:
VTUL_Distribution_License_2016_05_09.pdf
Size:
18.09 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

All Faculty Deposits
Scholarly Works, Small Animal Clinical Sciences